Allelix Biopharmaceuticals Inc.

Richard W Barnett

Martin Sumner-Smith

Lorne S Reid

Nahum Sonenberg

Michael Twist

Described herein are oligopeptides useful to inhibit replication of herpesviruses, especially herpes simplex viruses. In a preferred embodiment of the invention, the oligopeptide is a D-arginine nonamer having N- and C-terminal protecting groups, which, at a 5 uM concentration, exhibits greater than 95% inhibition of HSV-1 replication, in a standard assay.

Treatment of herpesvirus infection

Described herein are oligopeptides useful to inhibit replication in virally infected individuals. In a preferred embodiment of the invention, the oligopeptide is a D-arginine nonamer having N- and C-terminal protecting groups, which, at a 3 uM concentration, exhibits greater than 95% inhibition of HIV replication, in a standard assay.

Peptide-based inhibitors of HIV replication

Described herein are oligopeptides useful to inhibit replication in virally infected individuals. In a preferred embodiment of the invention, the oligopeptide is a D-arginine nonamer having N- and C-terminal protecting groups, which, at a 5 uM concentration, exhibits greater than 95% inhibition of HIV replication, in a standard assay.

Growing community of inventors

Mississauga, Canada

Richard W Barnett